CannaPharmaRX Files 8-K for Other Events
Ticker: CPMD · Form: 8-K · Filed: Oct 10, 2025 · CIK: 1081938
| Field | Detail |
|---|---|
| Company | Cannapharmarx, Inc. (CPMD) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financial-exhibits, company-update
TL;DR
CannaPharmaRX filed an 8-K on Aug 7th for 'Other Events' - check for updates.
AI Summary
CannaPharmaRX, Inc. filed an 8-K on October 10, 2025, reporting an event that occurred on August 7, 2025. The filing is categorized under 'Other Events' and includes 'Financial Statements and Exhibits'. The company, formerly known as Concord Ventures, Inc., Golden Dragon Holding Co., and CCVG, Inc., is incorporated in Delaware and headquartered in Calgary, Alberta, Canada.
Why It Matters
This 8-K filing indicates that CannaPharmaRX, Inc. has reported significant events or submitted financial exhibits, which could provide insights into the company's operational status or financial health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and financial exhibits, without immediate indication of significant negative developments.
Key Players & Entities
- CannaPharmaRX, Inc. (company) — Registrant
- August 7, 2025 (date) — Date of earliest event reported
- October 10, 2025 (date) — Filing date
- Concord Ventures, Inc. (company) — Former company name
- Golden Dragon Holding Co. (company) — Former company name
- CCVG, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Calgary, Alberta, Canada (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by CannaPharmaRX, Inc. on August 7, 2025?
The filing does not detail the specific 'Other Events' in the provided text, only that it falls under this category.
What is the significance of the 'Financial Statements and Exhibits' being filed?
The filing indicates that financial statements and exhibits are part of this report, suggesting updates or disclosures related to the company's financial condition or operations.
When was CannaPharmaRX, Inc. incorporated and where is its principal executive office located?
CannaPharmaRX, Inc. was incorporated in Delaware and its principal executive offices are located in Calgary, Alberta, Canada.
What were the previous names of CannaPharmaRX, Inc. and when did these name changes occur?
The company was formerly known as Concord Ventures, Inc. (name change date: 20071003), CCVG, Inc. (name change date: 20101117), and Golden Dragon Holding Co. (name change date: 20110125).
What is the Commission File Number and IRS Employer Identification No. for CannaPharmaRX, Inc.?
The Commission File Number is 333-251016 and the IRS Employer Identification No. is 27-4635140.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-10-10 11:53:59
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CPMD OTC Markets Indicat
Filing Documents
- canna_8k.htm (8-K) — 26KB
- canna_ex11.htm (EX-1.1) — 3KB
- canna_ex11img5.jpg (GRAPHIC) — 44KB
- canna_ex11img1.jpg (GRAPHIC) — 175KB
- canna_ex11img2.jpg (GRAPHIC) — 103KB
- canna_ex11img3.jpg (GRAPHIC) — 214KB
- canna_ex11img4.jpg (GRAPHIC) — 129KB
- 0001654954-25-011655.txt ( ) — 1055KB
- canna-20250807.xsd (EX-101.SCH) — 5KB
- canna-20250807_lab.xml (EX-101.LAB) — 14KB
- canna-20250807_cal.xml (EX-101.CAL) — 1KB
- canna-20250807_pre.xml (EX-101.PRE) — 9KB
- canna-20250807_def.xml (EX-101.DEF) — 2KB
- canna_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. CannaPharmaRX, Inc. ("the "Company") entered into letter agreements with payment schedules to address outstanding amounts due to two significant debtholders of the Company. The Company is entering into the payment schedule as a way to address outstanding debts and avoid additional defaults but retain capital to continue to grow operations and deliver product. Information about the payment schedules was previously included in the Company's 10Q for period ending June 30, 2025, however, the actual schedule agreements were erroneously not included. The Company is filing this 8-k to include the actual payment schedule agreement that were erroneously not included in the exhibits of the Company's 10Q for period ending June 30, 2025.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. The repayment schedules for the debtholders are being attached as an exhibit herewith. Exhibit No. Description 1.1 Letter Agreement (Payment Schedule) - A. Tal Payment Schedule (Payment Schedule) - Koze Investments 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CANNAPHARMARX, INC. October 3, 2025 By: /s/ Constantine Nkafu Name: Constantine Nkafu Title: CEO 3